亿帆医药：子公司注射用硫酸艾沙康唑获得药品注册证书

Core Viewpoint - The company announced that its wholly-owned subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the injection of Sulfate Isavuconazole, which is an anti-infection drug used for treating invasive fungal infections in adults [1] Company Summary - The injection of Sulfate Isavuconazole is specifically indicated for the treatment of invasive aspergillosis and invasive mucormycosis [1] - As of the date of the report, a total of 9 companies in China have received approval for the injection of Sulfate Isavuconazole, with several others undergoing review for generic drug applications [1] - The company has invested approximately 7.8972 million yuan in the research and development of Sulfate Isavuconazole [1]